Detalhe da pesquisa
1.
Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer - VinMetAtezo trial, (GFPC 04-2017).
Future Oncol;
16(4): 5-10, 2020 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31894704
2.
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo).
Lung Cancer;
178: 191-197, 2023 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36868180
3.
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).
Target Oncol;
18(6): 905-914, 2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37966566
4.
Management of patients with synchronous head-and-neck and lung cancers: SYNCHRON GFPC 15-01 study.
J Cancer Res Ther;
18(Supplement): S160-S164, 2022 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36510958
5.
Mid-term pulmonary sequelae after hospitalisation for COVID-19: The French SISCOVID cohort.
Respir Med Res;
82: 100933, 2022 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35905553
6.
Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study).
Lung Cancer;
161: 122-127, 2021 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34583220
7.
Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small-Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study).
Onco Targets Ther;
13: 13299-13305, 2020.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33408480
8.
Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study).
Target Oncol;
12(6): 833-838, 2017 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28762087
9.
Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-time monitoring of therapeutic response to tyrosine kinase inhibitors?
J Thorac Oncol;
9(7): e49-e50, 2014 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24926553
10.
Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients.
Lung Cancer;
82(2): 373-4, 2013 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24007628